Profile data is unavailable for this security.
About the company
Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.
- Revenue in USD (TTM)18.58m
- Net income in USD-145.47m
- Incorporated2016
- Employees174.00
- LocationGeneration Bio Co301 BINNEY STREETCAMBRIDGE 02142United StatesUSA
- Phone+1 (857) 529-5908
- Fax+1 (302) 655-5049
- Websitehttps://generationbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Relmada Therapeutics Inc | 0.00 | -86.49m | 82.98m | 20.00 | -- | 1.74 | -- | -- | -2.87 | -2.87 | 0.00 | 1.58 | 0.00 | -- | -- | 0.00 | -104.91 | -- | -116.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.09 | -- | -- | -- |
| PMV Pharmaceuticals Inc | 0.00 | -51.47m | 83.31m | 63.00 | -- | 0.421 | -- | -- | -0.9998 | -0.9998 | 0.00 | 3.82 | 0.00 | -- | -- | 0.00 | -21.24 | -21.16 | -22.36 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
| Fibrobiologics Inc | 0.00 | -17.78m | 83.53m | 10.00 | -- | 29.87 | -- | -- | -0.8864 | -0.8864 | 0.00 | 0.0807 | 0.00 | -- | -- | 0.00 | -149.60 | -- | -225.38 | -- | -- | -- | -- | -- | -- | -- | 0.0403 | -- | -- | -- | -272.15 | -- | -- | -- |
| Invivyd Inc | 11.56m | -225.14m | 83.59m | 94.00 | -- | 1.01 | -- | 7.23 | -1.95 | -1.95 | 0.0996 | 0.6953 | 0.0529 | -- | 2.48 | 123,021.30 | -103.08 | -- | -135.83 | -- | 92.27 | -- | -1,946.87 | -- | 1.58 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
| MDxHealth SA | 80.74m | -40.80m | 84.64m | 300.00 | -- | -- | -- | 1.05 | -1.54 | -1.54 | 3.06 | -0.3229 | 0.5906 | 9.39 | 7.49 | 269,136.70 | -29.85 | -51.62 | -43.63 | -64.72 | 62.64 | 50.88 | -50.54 | -117.64 | 0.8252 | -1.74 | 1.18 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Genelux Corp | 8.00k | -27.66m | 84.96m | 23.00 | -- | 2.54 | -- | 10,619.66 | -0.9537 | -0.9537 | 0.0003 | 0.9703 | 0.0002 | -- | -- | 347.83 | -74.41 | -- | -92.15 | -- | -- | -- | -345,750.00 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Generation Bio Co | 18.58m | -145.47m | 88.17m | 174.00 | -- | 0.8437 | -- | 4.74 | -2.19 | -2.19 | 0.2797 | 1.56 | 0.059 | -- | 56.31 | 106,793.10 | -46.16 | -36.96 | -51.29 | -39.21 | -- | -- | -782.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Inotiv Inc | 501.06m | -99.22m | 88.69m | 1.96k | -- | 0.487 | -- | 0.177 | -3.84 | -3.84 | 19.44 | 7.00 | 0.615 | 8.12 | 6.83 | 256,297.70 | -12.11 | -23.84 | -19.28 | -29.26 | 24.93 | 29.31 | -19.70 | -33.24 | 0.2279 | -0.6234 | 0.6774 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
| Quince Therapeutics Inc | 0.00 | -53.26m | 90.02m | 32.00 | -- | 2.00 | -- | -- | -1.25 | -1.25 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -50.27 | -42.72 | -52.16 | -46.06 | -- | -- | -- | -- | -- | -- | 0.249 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| Hillevax Inc | 0.00 | -150.28m | 90.65m | 90.00 | -- | 0.4886 | -- | -- | -3.09 | -3.09 | 0.00 | 3.73 | 0.00 | -- | -- | 0.00 | -51.15 | -- | -54.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.68 | -- | -- | -- |
| Cabaletta Bio Inc | 0.00 | -104.16m | 91.35m | 154.00 | -- | 0.5243 | -- | -- | -2.17 | -2.17 | 0.00 | 3.57 | 0.00 | -- | -- | 0.00 | -55.16 | -33.76 | -60.53 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
| Regulus Therapeutics Inc | 0.00 | -41.63m | 91.70m | 32.00 | -- | 1.06 | -- | -- | -1.08 | -1.08 | 0.00 | 1.33 | 0.00 | -- | -- | 0.00 | -63.31 | -53.74 | -71.29 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.00 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
| Oramed Pharmaceuticals, Inc. | 0.00 | 4.47m | 93.12m | 15.00 | 23.13 | 0.5937 | 20.21 | -- | 0.0999 | 0.0999 | 0.00 | 3.89 | 0.00 | -- | -- | 0.00 | 2.22 | -- | 2.79 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
| Assembly Biosciences Inc | 28.33m | -40.80m | 93.56m | 65.00 | -- | 3.60 | -- | 3.30 | -7.54 | -7.54 | 5.14 | 4.09 | 0.373 | -- | -- | 435,784.60 | -53.73 | -39.69 | -79.14 | -44.03 | -- | -- | -144.05 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
| Annovis Bio Inc | 0.00 | -40.94m | 93.68m | 6.00 | -- | 12.77 | -- | -- | -3.76 | -3.76 | 0.00 | 0.5318 | 0.00 | -- | -- | 0.00 | -333.05 | -106.31 | -523.91 | -124.71 | -- | -- | -- | -- | -- | -3.51 | 0.00 | -- | -- | -- | -121.90 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Generation Bio Co's reporting currency: US Dollar USD
48.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2024 | 9.25m | 13.85% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 5.32m | 7.97% |
| Bellevue Asset Management AGas of 30 Sep 2024 | 3.92m | 5.87% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 3.13m | 4.68% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.59m | 3.88% |
| Bank of America, NA (Private Banking)as of 30 Sep 2024 | 2.13m | 3.20% |
| EcoR1 Capital, LLCas of 30 Sep 2024 | 2.05m | 3.07% |
| Baker Bros. Advisors LPas of 30 Sep 2024 | 1.94m | 2.91% |
| Geode Capital Management LLCas of 30 Sep 2024 | 1.14m | 1.71% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 992.19k | 1.49% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
